David G Winkler, Kerrie L Faia, Jonathan P DiNitto, Janid A Ali, Kerry F White, Erin E Brophy, Melissa M Pink, Jennifer L Proctor, Jennifer Lussier, Christian M Martin, Jennifer G Hoyt, Bonnie Tillotson, Erin L Murphy, Alice R Lim, Brian D Thomas, John R Macdougall, Pingda Ren, Yi Liu, Lian-Sheng Li, Katti A Jessen, Christian C Fritz, Joi L Dunbar, James R Porter, Christian Rommel, Vito J Palombella, Paul S Changelian, Jeffery L Kutok
Phosphoinositide-3 kinase (PI3K)-δ and PI3K-γ are preferentially expressed in immune cells, and inhibitors targeting these isoforms are hypothesized to have anti-inflammatory activity by affecting the adaptive and innate immune response. We report on a potent oral PI3K-δ and PI3K-γ inhibitor (IPI-145) and characterize this compound in biochemical, cellular, and in vivo assays. These studies demonstrate that IPI-145 exerts profound effects on adaptive and innate immunity by inhibiting B and T cell proliferation, blocking neutrophil migration, and inhibiting basophil activation...
November 21, 2013: Chemistry & Biology